Alternative Splicing Yields Insights Into Cancer Metabolism And Potential New Drug Targets
This article was originally published in Start Up
Executive Summary
For the first time, cancer researchers have shown that a variant of the EGF receptor often amplified in glioblastoma upregulates a specific splicing protein that in turn alters cancer metabolism. This increased understanding of the factors controlling so-called “alternative splicing” could offer up a range of new therapeutic approaches in GBM, other cancers, and potentially other diseases.